PerkinElmer to Showcase Expanded Life Science / Cell & Gene Therapy Portfolios and Automated Genomic Workflows at SLAS 2022

PerkinElmer to Showcase Expanded Life Science / Cell & Gene Therapy Portfolios and Automated Genomic Workflows at SLAS 2022

February 3, 2022 at 11:30 AM EST

End-to-end solutions designed to help scientists streamline and improve
drug discovery R&D productivity

WHAT:  PerkinElmer, Inc., a global leader committed to innovating for a healthier world, is at SLAS 2022 on February 7-9 along with several of its new partner companies showcasing how its end-to-end life science solutions and automated workflows can accelerate scientists’ R&D productivity and in turn get the right therapeutic candidates to market faster. The differentiated offerings and novel workflows being highlighted include instruments, assays and reagents, consumables, automation technologies, software and services that span across basic research, biologics, and cell and gene drug discovery and development.

HOW: Innovators from across PerkinElmer and its new partner companies Horizon Discovery,  BioLegend, Nexcelom Bioscience and Omni International are in Boston for the industry gathering sharing leading technologies and solutions critical for today’s labs -- from automation, liquid handling, high-content screening, cell painting, multimode detection, gene editing tools and functional genomic screening services and libraries, to cell counting, antibodies for flow cytometry, recombinant proteins and no-wash immunoassay kits.

PerkinElmer is unveiling a walkaway workflow solution for protein-protein interaction (PPI) immunoassay development. This workflow is fully automated once the reagents are placed on the JANUS® G3 Assay Development Workstation integrated with the VICTOR™ Nivo®  multimode microplate reader. No automation programing is required, as TIBCO® Spotfire®  software is configured as a graphical user interface (GUI) to interactively design plate layouts and add meta data by user input. The solution is enabled through homogeneous time resolved fluorescence (HTRF®) immunoassay technology which requires no wash steps.  Signals VitroVivo™ software is used for analyzing the data and as a recommendation engine to provide conditions for the next set of experiments. The workflow components are integrated for a complete data flow with rationale and traceability of each well fully documented.

Also on display will be the FlexDrop™ iQ™ Non-contact Dispenser. To further reduce the cost and time associated with the drug discovery process, it provides rapid and precise dispensing as low as eight nanoliters and can be programmed and run from the integrated touch screen.

Additionally, the Honeycomb Biotechnologies, Inc. HIVE™ scRNAseq solution for single-cell isolation and analysis is being featured at SLAS. It leverages a portable handheld device for the capture, storage and RNA-Seq library prep of a diverse range of cell types, requires no specialized instrumentation, and expands opportunities for laboratories pursuing basic, translational, preclinical, and clinical research.

MORE: PerkinElmer and its partner company experts will also deliver several presentations ranging from advancements in pooled and arrayed CRISPR-Cas9 screening, next-generation HCS data management and analysis, and cell counting to PPI assay development and more. PerkinElmer has also broadened its collaboration with biotechs and will jointly present two outcomes: An orthogonal approach for antibody characterization by high throughput Surface Plasmon Resonance (HT SPR) with Carterra and combined no-wash immunoassay by PerkinElmer’s AlphaLISA® kit. A new concept for target engagement using CETSA®ble kits will be presented with the Swedish Pelago Biosciences team. Additionally, Dr. Daniel LaBarbera, from The Center for Drug Discovery at the University of Colorado Anschutz Medical Campus will discuss his new lab’s use of PerkinElmer’s high throughput drug discovery technologies for cancer research. For complete details, view the full presentation schedule.

“The life science industry is changing the way it does drug discovery and development and PerkinElmer is changing too,” said Alan Fletcher, senior vice president life science at PerkinElmer. “Together with our strategic company partners, our expanded scientific portfolio and multi-disciplined team create unique synergies and a blended offering to help our customers overcome challenges in speed, productivity, and success rates.”

About PerkinElmer

PerkinElmer is a leading, global provider of end-to-end solutions that help scientists, researchers and clinicians better diagnose disease, discover new and more personalized drugs, monitor the safety and quality of our food, and drive environmental and applied analysis excellence. With an 85-year legacy of advancing science and a mission of innovating for a healthier world, our dedicated team of more than 16,000 collaborates closely with commercial, government, academic and healthcare customers to deliver reagents, assays, instruments, automation, informatics and strategic services that accelerate workflows, deliver actionable insights and support improved decision making. We are also deeply committed to good corporate citizenship through our dynamic ESG and sustainability programs. The Company reported revenues of approximately $5.0 billion in 2021, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at Follow PerkinElmer on LinkedIn, Twitter, Facebook, Instagram, and YouTube.


Media Contacts
Chet Murray
+1 781.462.5126 |

Mary Karpa
+1 215.896.4022 |

Related Links

IR Contact
(781) 663 - 6900
940 Winter Street
Waltham, MA 02451
United States

Transfer Agent

Mailing addresses
Correspondence should be mailed to:
P.O. Box 505000
Louisville, KY 40233

Overnight correspondence should be sent to:
462 South 4th Street, Suite 1600
Louisville, KY 40202

Shareholder website
Shareholder online inquiries